Related Experiment Videos
[How I treat...chronic myeloid leukemia]
K Hafraoui1, S Humblet-Baron, F Baron
1Département de Médecine, Service d'Hématologie, Université de Liège.
Revue Medicale De Liege
|March 22, 2003
Summary
The tyrosine kinase BCR/ABL is key in chronic myeloid leukemias (CML). STI571 (imatinib mesylate) effectively treats CML, with algorithms aiding patient management.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Context:
- Chronic myeloid leukemia (CML) is characterized by the BCR/ABL tyrosine kinase.
- Targeted therapy development is crucial for CML treatment.
Purpose:
- To review the identification of BCR/ABL as a CML hallmark.
- To discuss the efficacy of the BCR/ABL inhibitor STI571 (imatinib mesylate) in CML treatment.
Summary:
- This review details the discovery of BCR/ABL in CML and the development of STI571.
- Phase I and II trial results demonstrate STI571's effectiveness in CML patients.
- Simplified algorithms are proposed to guide clinical decision-making for CML management.
Impact:
- Establishes STI571 as a targeted therapy for CML.
- Provides evidence supporting the use of imatinib mesylate in CML treatment.
- Offers clinical guidance for optimizing CML patient care.